Hepatitis C Patient Journey: Fight for the Cure

In part seven, Jim Wilson, RPh, MBA, president of WilsonRx, offers advice to patients with hepatitis C who are unable to access curative medications.
PUBLISHED WEDNESDAY, DECEMBER 2, 2015
In part seven, Jim Wilson, RPh, MBA, president of WilsonRx, offers advice to patients with hepatitis C who are unable to access curative medications.
 
Wilson was infected with an acute case of Non-A/Non-B hepatitis in 1975 due to a tainted blood supply but was not diagnosed with the disease until 1999. After receiving a liver transplant in 2006, he was finally cured of HCV in 2012 after enrolling in a 12-week clinical trial of the drug Harvoni.
 


 
Recommended Articles
Study finds a common assortment of reasons for non-initiation of HCV therapy, regardless of patient race or ethnicity.
Managing the risk of hepatitis C and liver disease among infants born to mothers with chronic HCV is a challenge.
HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.
Anti-retroviral drug therapy may effectively treat hepatitis C-HIV coinfection.
$auto_registration$